What are your management strategies for patients with chronic kidney disease attributed to deferasirox use who require frequent blood products for a hematologic disorder?

It depends on the type and severity of the hematological disorder as well as the extent of CKD. Currently, two oral chelators; deferasirox and deferiprone, are available, in addition to deferoxamine, which can be administered SubQ or IV. These can be mixed and combined, and combination therapy may be considered in cases where patients cannot tolerate a full dose of one chelator. Deferipron + desferal and deferasirox + desferal have been used in thalassemia routinely and there is published data o...